disease interaction(s) of rheumatoid arthritis with osteoporosis
Jump to navigation
Jump to search
Management
- denosumab in combination with biological response modifier may not increase risk of infection [1]
More general terms
References
- ↑ 1.0 1.1 Curtis JR et al. Risk of hospitalized infection among rheumatoid arthritis patients concurrently treated with a biologic agent and denosumab. Arthritis Rheumatol 2015 Jun; 67:1456 PMID: https://www.ncbi.nlm.nih.gov/pubmed/25708920